Skip to main content
IONS
NASDAQ Life Sciences

Ionis/Otsuka ALS Drug Hits Primary Goal in Late-Stage Trial

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$46.42
Mkt Cap
$7.462B
52W Low
$44.2
52W High
$86.74
52W Position info
5.0% above low
Off High info
46% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

IONS is trading near its 52-week low of $44.2 (5.0% above the low).

Summary

Ulefnersen, Ionis's partnered ALS drug with Otsuka, met its primary endpoint in a Phase 3 trial for FUS-ALS, a rare inherited form of the disease with no approved treatments. The drug improved function and survival versus placebo, reduced nerve damage markers, and showed a favorable safety profile. Ionis Pharmaceuticals says ulefnersen demonstrates favorable safety and tolerability profile. This is a major pipeline win for Ionis, which has faced recent setbacks including the eplontersen ATTR-CM failure and pelacarsen miss. The companies plan to pursue accelerated approval with the FDA and other regulators, potentially bringing the first targeted therapy for FUS-ALS to market. An early access program has also been launched, underscoring the unmet need and commercial urgency.

At the time of this announcement, IONS was trading at $46.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5B. The 52-week trading range was $44.20 to $86.74. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

IONS - Latest Insights

IONS
Nov 17, 2026, 3:03 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $28.02
Real-time Price: $28.00 info
Change: -$0.017 (-0.06%) info
Market Cap: $4.665B info
IONS
Nov 10, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $31.17
Real-time Price: $28.00 info
Change: -$3.17 (-10%) info
Market Cap: $4.665B info
IONS
Nov 09, 2026, 11:01 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $28.67
Real-time Price: $28.00 info
Change: -$0.662 (-2%) info
Market Cap: $4.665B info
IONS
Nov 09, 2026, 8:33 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.50
Real-time Price: $28.00 info
Change: -$3.50 (-11%) info
Market Cap: $4.665B info
IONS
Nov 09, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $37.00
Real-time Price: $28.00 info
Change: -$9.00 (-24%) info
Market Cap: $4.665B info